001_Delcath_CorporateLogo_Tagline.png
Delcath Systems, Inc. Announces First Quarter 2021 Results
May 11, 2021 08:00 ET | Delcath Systems, Inc.
NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems Schedules Conference Call to Report 2021 First Quarter Financial Results
April 30, 2021 16:01 ET | Delcath Systems, Inc.
NEW YORK, April 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
April 30, 2021 09:00 ET | Delcath Systems, Inc.
A Presentation of Positive Preliminary Efficacy Results from the FOCUS Phase III trial Company Q&A Webinar Scheduled for Monday, June 7, 2021 at 8:30am ET NEW YORK, April 30, 2021 ...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems, Inc. Announces Revised NICE Guidance for CHEMOSAT in the United Kingdom
April 21, 2021 08:38 ET | Delcath Systems, Inc.
NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems, Inc. Shares Additional Information Regarding FOCUS Trial Power Calculation
March 31, 2021 14:55 ET | Delcath Systems, Inc.
NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems, Inc. Announces Fourth Quarter 2020 Results, Highlights Preliminary Positive FOCUS Trial Results; Conference Call Today at 8:00am Eastern Time
March 31, 2021 07:45 ET | Delcath Systems, Inc.
NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems, Inc. Announces Positive Preliminary Results from Phase 3 FOCUS Trial of HEPZATO in Patients with Metastatic Ocular Melanoma
March 31, 2021 07:30 ET | Delcath Systems, Inc.
Based on Preliminary Data, FOCUS Trial Achieves Prespecified Success Threshold Conference Call Today at 8:00am Eastern Time NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc....
Delcath Systems Schedules Conference Call to Report 2020 Fourth Quarter Financial Results
March 24, 2021 16:01 ET | Delcath Systems, Inc.
NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
Delcath Systems to Participate at Upcoming Virtual Investor Conferences
March 08, 2021 09:00 ET | Delcath Systems, Inc.
NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
Delcath Systems to Participate at Upcoming Virtual Investor Conferences
February 11, 2021 09:00 ET | Delcath Systems, Inc.
NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...